Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | MET | P08581 | 6/20 | 0.39 |
| ▸ | INSR | P06213 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030763 | 0.91 | AXL (0.43) | AXLALDH1A1KMT2AKITSCN9A | |
| SCHEMBL11031935 | 0.91 | AXL (0.48) | AXLEGFRMETINSR | |
| SCHEMBL11030275 | 0.90 | AXL (0.42) | AXLALDH1A1KMT2ASCN9AEGFR | |
| SCHEMBL11027302 | 0.89 | AXL (0.52) | AXLEGFRMETINSR | |
| SCHEMBL11032009 | 0.88 | AXL (0.46) | AXLALDH1A1SCN9AEGFRMET | |
| SCHEMBL11031202 | 0.88 | AXL (0.40) | AXLSCN9AEGFRMET | |
| SCHEMBL11028680 | 0.87 | AXL (0.49) | AXLEGFRMET | |
| SCHEMBL12873682 | 0.86 | AXL (0.41) | AXLEGFRMET | |
| SCHEMBL1161306 | 0.86 | AXL (0.41) | AXLSCN9AEGFRMET | |
| SCHEMBL11028053 | 0.86 | AXL (0.43) | AXLALDH1A1KMT2AKITEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2461869-A1 | NOVEL BICYCLIC UREA COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | AXL 1732/4885ALDH1A1 1372/4885KMT2A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.